<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287129</url>
  </required_header>
  <id_info>
    <org_study_id>MEM-0000-SIV-0028-I</org_study_id>
    <nct_id>NCT02287129</nct_id>
  </id_info>
  <brief_title>Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction</brief_title>
  <acronym>MEMORI</acronym>
  <official_title>Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic and Molecular Response evaluation for the individualization of therapy in
      adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for
      patients with metabolically (ie, according to PET criteria) chemotherapy-resistant locally
      advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy (INRCT). Additonal
      efforts will be done by investigation of molecular and metabolic biomarkers in relation to
      their predictive and prognostic value by correlating them with histopathologic responses and
      clinical outcome in an exploratory approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adenocarcinomas of the esophagus and the esophagogastric junction (AEG) are
      clinically-topographically divided into subtypes I-III according to the Siewert
      classification and show an increased incidence. Neoadjuvant and/or perioperative chemotherapy
      or preoperative radiochemotherapy is well established in the management of AEG. However, a
      significant number of patients do not respond to preoperative chemotherapy, suffering from
      toxicity and facing a worse outcome due to lower R0 resection rates. Previous results from
      the MUNICON-1 and MUNICON-2 trials have shown that PET-based therapy individualization can be
      successfully integrated in neoadjuvant treatment algorithms.

      Tumor-free resection edges (R0) constitute the greatest prognostic advantage in terms of
      overall survival. However, the R0 resection rates for patients who, according to early
      metabolic response evaluation, have not responded to the chemotherapy, have not been
      satisfactory, even after conversion to an - albeit moderate - radiochemotherapy in the
      MUNICON-2 trial. Thus, this patient population (so-called non responders) so far lack a
      beneficial neoadjuvant therapy modality.

      Based on these results, the primary goal of MEMORI study is to evaluate the R0 resection rate
      for patients with metabolically (ie, according to PET criteria) chemotherapy-resistant
      locally advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy (INRCT).
      Secondary it is planned to investigate molecular and metabolic biomarkers in relation to
      their predictive and prognostic value by correlating them with histopathologic responses and
      clinical outcome in an exploratory approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 day of surgery (in between day 28 to day 43 after radio-chemotherapy)</time_frame>
    <description>R0 resection rate of patients suffering from metabolically (following PET criteria) chemotherapy-resistant, locally advanced AEG, who receive a more intensive neoadjuvant radio-chemotherapy (INRCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regression</measure>
    <time_frame>1 day of surgery (in between day 28 to day 43 after radio-chemotherapy)</time_frame>
    <description>Histological regression defined by Becker Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from day 0 to follow up visit 6 (24 months after surgery)</time_frame>
    <description>Overall survival defined as period from start of study to death (if necessary censored by end of follow-up period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>from day 0 to follow up visit 6 (24 months after surgery)</time_frame>
    <description>Disease-free survival, defined as period from start of study to earlier occurring event: death or relapse until end of follow-up; Relapse will be separated into events of &quot;local failure&quot;, &quot;distant failure&quot; and &quot;local and distant failure&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>from day 0 to follow up visit 6 (24 months after surgery)</time_frame>
    <description>Quality of life, analyzed via EORTC QLQ-C30 and EORTC QLQ-OG25 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabilic response rate</measure>
    <time_frame>from day 0 to one time point of time period day 14 to 28 after chemotherapy</time_frame>
    <description>Metabolic response rate under neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational analysis</measure>
    <time_frame>1 day of surgery (in between day 28 to day 43 after radio-chemotherapy)</time_frame>
    <description>Translational analysis for identification of tumor determinants relevant for prognosis and therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from day 0 to follow up visit 6 (24 months after surgery)</time_frame>
    <description>Occurence of AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Adenocarcinoma of the Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_label>Responder</arm_group_label>
    <other_name>Oxaliplan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50 mg/m2</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_label>Responder</arm_group_label>
    <other_name>Epi Teva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625 mg/m2</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_label>Responder</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>200 mg/m2</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_label>Responder</arm_group_label>
    <other_name>5-FU medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>2 mg/ml min</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <other_name>Carboplatin SUN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>50 mg/m2</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <other_name>Taxomedac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>total dosage 41,4 Gy</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <other_name>intensitive neoadjuvant radiochemotherapy (INRCT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>translational analysis</description>
    <arm_group_label>Non-Responder</arm_group_label>
    <arm_group_label>Responder</arm_group_label>
    <other_name>esophagogastroduodenoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed AEG I-III

          -  Potentially R0 - resectable AEG and primary tumor category UT2 -4

          -  Functional operability : Exclusion of OP - limiting comorbidities

          -  Intense FDG tracer uptake of the tumor during Baseline PET/CT examination and thus
             suitability for monitoring and early response prediction by FDG - PET ( [ 18F ] - FDG
             uptake in the tumor at baseline &gt; 1.35 x liver SUV + 2 x standard deviation of the
             liver SUV)

          -  Performance status (ECOG ) 0 or 1

          -  Age : ≥ 18

          -  creatinine clearance &gt; 60ml/min measured in a 24 h urine or calculated with the
             Cockgroft -Gault formula

          -  bilirubin ≤ 1.5 times upper limit of normal , serum transaminases (GOT

             / GPT ) ≤ 3 times ULN

          -  leukocytes ≥ 3.5 g / l, platelet ≥ 100 g / l

          -  Negative pregnancy test (determination of beta- HCG in urine or serum) in women of
             childbearing potential

          -  A signed consent form after implementation of medical education

        Exclusion Criteria:

          -  Existing distant metastases (M1b)

          -  Tumor infiltration into the tracheobronchial system

          -  Previous radiotherapy targeted at the thorax

          -  Lack of ability of the patient to adhere to the protocol rules

          -  Manifest heart failure despite optimal medication&gt; NYHA I

          -  existing angina pectoris at rest or undergoing stress without clarification via
             interventional cardiology and / or myocardial infarction within the last 6 months

          -  Existing pregnancy or lactation

          -  childbearing or fertility without using recognized safe methods of contraception

          -  Coexisting other malignant diseases with the exception of a non-melanomatuous,
             localized skin tumor or carcinoma in situ of the cervix

          -  absence of a signed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Siveke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>II. Medizinische Klinik, Klinikum rechts der Isar (MRI) der TUM,Ismaninger Str. 22</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Barta, Dr.</last_name>
    <phone>0049(0)89-4140</phone>
    <phone_ext>7787</phone_ext>
    <email>sabine.barta@mri.tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd department of the Medical Clinic of the Technical University Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Siveke, MD</last_name>
      <phone>0049-89-4140</phone>
      <phone_ext>6706</phone_ext>
      <email>jens.siveke@lrz.tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Potentially R0 - resectable AEG and primary tumor category</keyword>
  <keyword>Histologically confirmed AEG I-III</keyword>
  <keyword>Functional operability</keyword>
  <keyword>Intense FDG tracer uptake of the tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

